The study results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with T2D. Additionally, mazdutide treatment improved several cardiometabolic risk factors, including blood pressure, lipids, serum uric acid and liver enzymes. Detailed results will be published in peer-reviewed journals.
Reported Earlier, Innovent's Phase 3 DREAMS-2 Trial Shows Mazdutide's Superiority Over Dulaglutide In Chinese Type 2 Diabetes Patients At EASD 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.